Two Sigma Advisers’s Trillium Therapeutics Inc. TRIL Stock Holding History

Two Sigma Advisers’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-47,000	Closed	-$825K	–	2884
2021 Q3	$825K	Sell	47,000 -65,500	-58%	-$765K	﹤0.01%	1708
2021 Q2	$1.09M	Sell	112,500 -78,400	-41%	-$738K	﹤0.01%	1593
2021 Q1	$2.05M	Sell	190,900 -47,900	-20%	-$592K	0.01%	1257
2020 Q4	$3.51M	Sell	238,800 -43,500	-15%	-$627K	0.01%	974
2020 Q3	$4.01M	Sell	282,300 -63,700	-18%	-$635K	0.01%	846
2020 Q2	$2.8M	Buy	346,000 +26,200	+8%	+$162K	0.01%	1040
2020 Q1	$1.29M	Buy	319,800 +291,100	+1,014%	+$1.1M	﹤0.01%	1344
2019 Q4	$30K	Hold	28,700	–	–	﹤0.01%	2311
2019 Q3	$9K	Buy	+28,700	New	+$9.7K	﹤0.01%	2194

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Two Sigma Advisers's TRIL Position: Q4 2021 in Review

Two Sigma Advisers sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 47,000 shares — an estimated $825K sold.

Two Sigma Advisers first reported a position in TRIL in Q3 2019 and held it in 9 quarters. The position peaked at $4.01M in Q3 2020. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Two Sigma Advisers reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Two Sigma Advisers sold 47,000 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $825K.
Two Sigma Advisers first reported a position in Trillium Therapeutics Inc. in Q3 2019 and held it in 9 quarters.
Two Sigma Advisers's Trillium Therapeutics Inc. position peaked at $4.01M in Q3 2020.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Two Sigma Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.